• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Metagenomi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    3/17/25 4:06:44 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGX alert in real time by email
    8-K
    false000178527900017852792025-03-172025-03-17

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 17, 2025

     

     

    Metagenomi, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41949

    81-3909017

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    5959 Horton Street

    7th Floor

     

    Emeryville, California

     

    94608

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (510) 871-4880

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    MGX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 17, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the year ended December 31, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.

    Item 7.01 Regulation FD Disclosure.

    A copy of the Company’s March 2025 corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information contained in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description

    99.1

     

    Press Release Issued by Metagenomi, Inc. on March 17, 2025

    99.2

     

    Corporate Presentation of Metagenomi, Inc. dated March 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Metagenomi, Inc.

     

     

     

     

    Date:

    March 17, 2025

    By:

    /s/ Brian C. Thomas

     

     

     

    Brian C. Thomas, Ph.D.
    Chief Executive Officer

     


    Get the next $MGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGX

    DatePrice TargetRatingAnalyst
    5/7/2024$10.00Buy
    H.C. Wainwright
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    3/5/2024Outperform
    TD Cowen
    3/5/2024$22.00Outperform
    BMO Capital Markets
    3/5/2024$16.00Overweight
    JP Morgan
    3/5/2024$23.00Buy
    Jefferies
    3/5/2024$21.00Buy
    Chardan Capital Markets
    3/5/2024$25.00Overweight
    Wells Fargo
    More analyst ratings

    $MGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Metagenomi with a new price target

      H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

      5/7/24 6:26:47 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi downgraded by JP Morgan with a new price target

      JP Morgan downgraded Metagenomi from Overweight to Neutral and set a new price target of $6.00 from $16.00 previously

      5/2/24 6:29:35 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Metagenomi

      TD Cowen initiated coverage of Metagenomi with a rating of Outperform

      3/5/24 7:45:11 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wapnick Pamela was granted 14,000 shares, increasing direct ownership by 23% to 73,684 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:31 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Thomas Brian C. was granted 32,000 shares, increasing direct ownership by 1% to 2,528,276 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:17 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Irish Jian was granted 23,000 shares, increasing direct ownership by 8% to 321,933 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:57:48 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metagenomi to Present at Upcoming Scientific Meetings

      EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually. TIDES USA Oral Presentation Details: Title: AI-Guided Metagenomic Discovery of Compact CRISPR Systems for

      5/2/25 7:00:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Reports Business Updates and Full Year 2024 Financial Results

      Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025 Well capitalized with $248.3 million in cash, cash equivalents and available-for-sale marketable securities at the end of Q4 2024; Cash runway anticipated

      3/17/25 4:05:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

      Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its pr

      3/13/25 6:19:32 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Financials

    Live finance-specific insights

    See more
    • Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

      Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced data from an ongoing preclinical

      9/3/24 4:05:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

      EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1

      5/1/24 4:00:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MGX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      11/6/24 4:35:15 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      5/10/24 6:40:45 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metagenomi Announces New Appointment to its Board of Directors

      EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025. "We are excited to welcome Eric to our Board of Directors," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an in

      1/15/25 8:55:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Metagenomi Inc.

      DEFA14A - Metagenomi, Inc. (0001785279) (Filer)

      4/28/25 4:05:03 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Metagenomi Inc.

      DEF 14A - Metagenomi, Inc. (0001785279) (Filer)

      4/28/25 4:01:09 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Metagenomi Inc.

      EFFECT - Metagenomi, Inc. (0001785279) (Filer)

      3/26/25 12:15:18 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care